Assembly Biosciences (ASMB) Competitors $18.75 +0.53 (+2.91%) Closing price 04:00 PM EasternExtended Trading$18.71 -0.04 (-0.21%) As of 07:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ASMB vs. NKTR, OMER, CPIX, LLY, JNJ, ABBV, MRK, PFE, BMY, and ZTSShould you be buying Assembly Biosciences stock or one of its competitors? The main competitors of Assembly Biosciences include Nektar Therapeutics (NKTR), Omeros (OMER), Cumberland Pharmaceuticals (CPIX), Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), Merck & Co., Inc. (MRK), Pfizer (PFE), Bristol Myers Squibb (BMY), and Zoetis (ZTS). These companies are all part of the "pharmaceuticals" industry. Assembly Biosciences vs. Its Competitors Nektar Therapeutics Omeros Cumberland Pharmaceuticals Eli Lilly and Company Johnson & Johnson AbbVie Merck & Co., Inc. Pfizer Bristol Myers Squibb Zoetis Nektar Therapeutics (NASDAQ:NKTR) and Assembly Biosciences (NASDAQ:ASMB) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, earnings, institutional ownership, analyst recommendations, valuation, dividends and media sentiment. Is NKTR or ASMB more profitable? Assembly Biosciences has a net margin of -124.15% compared to Nektar Therapeutics' net margin of -152.49%. Assembly Biosciences' return on equity of -131.77% beat Nektar Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Nektar Therapeutics-152.49% -329.54% -55.24% Assembly Biosciences -124.15%-131.77%-36.81% Which has more volatility & risk, NKTR or ASMB? Nektar Therapeutics has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500. Comparatively, Assembly Biosciences has a beta of 0.62, suggesting that its stock price is 38% less volatile than the S&P 500. Do analysts rate NKTR or ASMB? Nektar Therapeutics presently has a consensus price target of $88.33, indicating a potential upside of 253.19%. Assembly Biosciences has a consensus price target of $33.00, indicating a potential upside of 76.00%. Given Nektar Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Nektar Therapeutics is more favorable than Assembly Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nektar Therapeutics 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86Assembly Biosciences 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Which has better earnings and valuation, NKTR or ASMB? Assembly Biosciences has lower revenue, but higher earnings than Nektar Therapeutics. Assembly Biosciences is trading at a lower price-to-earnings ratio than Nektar Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNektar Therapeutics$98.43M3.15-$118.96M-$9.60-2.61Assembly Biosciences$28.52M5.02-$40.18M-$6.23-3.01 Does the media refer more to NKTR or ASMB? In the previous week, Nektar Therapeutics had 6 more articles in the media than Assembly Biosciences. MarketBeat recorded 13 mentions for Nektar Therapeutics and 7 mentions for Assembly Biosciences. Nektar Therapeutics' average media sentiment score of 0.69 beat Assembly Biosciences' score of 0.33 indicating that Nektar Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nektar Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Assembly Biosciences 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders & institutionals believe in NKTR or ASMB? 75.9% of Nektar Therapeutics shares are owned by institutional investors. Comparatively, 19.9% of Assembly Biosciences shares are owned by institutional investors. 5.3% of Nektar Therapeutics shares are owned by company insiders. Comparatively, 5.3% of Assembly Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummaryNektar Therapeutics beats Assembly Biosciences on 9 of the 16 factors compared between the two stocks. Get Assembly Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ASMB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ASMB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ASMB vs. The Competition Export to ExcelMetricAssembly BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$139.16M$3.89B$5.61B$9.11BDividend YieldN/A1.24%5.24%4.01%P/E Ratio-3.014.9719.7619.92Price / Sales5.0211.92430.8999.65Price / CashN/A6.4037.4658.16Price / Book3.572.798.045.49Net Income-$40.18M-$109.62M$3.18B$250.27M7 Day Performance3.31%9.21%3.72%4.78%1 Month Performance9.97%11.60%3.72%7.20%1 Year Performance31.12%22.08%29.92%17.27% Assembly Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ASMBAssembly Biosciences3.7474 of 5 stars$18.75+2.9%$33.00+76.0%+31.7%$139.16M$28.52M-3.01100NKTRNektar Therapeutics4.1204 of 5 stars$23.47-5.2%$84.17+258.6%+25.8%$307.20M$98.43M-2.45220Analyst ForecastAnalyst RevisionHigh Trading VolumeOMEROmeros3.5998 of 5 stars$3.08-3.8%$18.00+484.4%-14.6%$187.50MN/A-1.16210News CoverageCPIXCumberland Pharmaceuticals1.1054 of 5 stars$3.04-3.5%N/A+133.6%$47.13M$37.87M-12.1680Trending NewsLLYEli Lilly and Company4.982 of 5 stars$772.82-1.0%$1,011.61+30.9%-15.9%$739.87B$45.04B62.8847,000Trending NewsAnalyst ForecastAnalyst RevisionJNJJohnson & Johnson4.7708 of 5 stars$155.23-0.5%$170.88+10.1%+5.6%$375.37B$88.82B17.27138,100Trending NewsUpcoming EarningsAnalyst ForecastABBVAbbVie4.4956 of 5 stars$187.44-1.0%$211.29+12.7%+16.0%$334.34B$56.33B79.7655,000Trending NewsAnalyst RevisionMRKMerck & Co., Inc.4.9963 of 5 stars$80.890.0%$109.19+35.0%-34.0%$203.22B$64.17B11.7775,000Trending NewsAnalyst ForecastAnalyst RevisionPFEPfizer4.9685 of 5 stars$25.23-0.6%$28.55+13.2%-9.1%$144.29B$62.46B18.2881,000Trending NewsAnalyst RevisionBMYBristol Myers Squibb4.8944 of 5 stars$46.50-0.9%$58.00+24.7%+18.1%$95.49B$48.30B17.4234,100Trending NewsAnalyst ForecastAnalyst RevisionZTSZoetis4.8321 of 5 stars$156.98-1.4%$212.13+35.1%-8.5%$70.87B$9.26B28.1813,800Positive News Related Companies and Tools Related Companies Nektar Therapeutics Alternatives Omeros Alternatives Cumberland Pharmaceuticals Alternatives Eli Lilly and Company Alternatives Johnson & Johnson Alternatives AbbVie Alternatives Merck & Co., Inc. Alternatives Pfizer Alternatives Bristol Myers Squibb Alternatives Zoetis Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ASMB) was last updated on 7/11/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Assembly Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Assembly Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
